Delving into the Latest Updates on HS-20110 with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

Target

CDH17

Mechanism

CDH17 modulators(Cadherin-17 modulators)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Shanghai Hansoh Biomedical Co. Ltd.

Active Organization

Changzhou Humon Pharmaceutical Co., Ltd.

Shanghai Hansoh Biomedical Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Ia期：主要研究目的：评价HS-20110在晚期实体瘤受试者中的安全性和耐受性次要研究目的：评价HS-20110在晚期实体瘤受试者中的有效性；评价HS-20110在晚期实体瘤受试者中的药代动力学（PK）特征；评价HS-20110在晚期实体瘤受试者中的免疫原性 Ib期：主要研究目的：评价HS-20110在晚期实体瘤受试者中的有效性；确认HS-20110的II期推荐剂量（RP2D）次要研究目的：评价HS-20110在晚期实体瘤受试者中的其他安全性指标；评价HS-20110在晚期实体瘤受试者中的其他有效性指标；评价HS-20110在晚期实体瘤受试者中的PK特征；评价HS-20110在晚期实体瘤受试者中的免疫原性

[Translation]

Phase Ia: Main study objective: To evaluate the safety and tolerability of HS-20110 in subjects with advanced solid tumors Secondary study objectives: To evaluate the efficacy of HS-20110 in subjects with advanced solid tumors; To evaluate the pharmacokinetic (PK) characteristics of HS-20110 in subjects with advanced solid tumors; To evaluate the immunogenicity of HS-20110 in subjects with advanced solid tumors Phase Ib: Main study objective: To evaluate the efficacy of HS-20110 in subjects with advanced solid tumors; To confirm the Phase II recommended dose (RP2D) of HS-20110 Secondary study objectives: To evaluate other safety indicators of HS-20110 in subjects with advanced solid tumors; To evaluate other efficacy indicators of HS-20110 in subjects with advanced solid tumors; To evaluate the PK characteristics of HS-20110 in subjects with advanced solid tumors; To evaluate the immunogenicity of HS-20110 in subjects with advanced solid tumors

Start Date-

Sponsor / Collaborator

Shanghai Hansoh Biomedical Co. Ltd.

[+1]

100 Clinical Results associated with HS-20110

Login to view more data

100 Translational Medicine associated with HS-20110

Login to view more data

100 Patents (Medical) associated with HS-20110

Login to view more data

100 Deals associated with HS-20110

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	CN	Shanghai Hansoh Biomedical Co. Ltd.	14 Jan 2025
Advanced Malignant Solid Neoplasm	Phase 1	CN	Changzhou Humon Pharmaceutical Co., Ltd.	14 Jan 2025